Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2003-05

AUTHORS

C. Goetz, P. Riva, G. Poepperl, F.J. Gildehaus, A. Hischa, K. Tatsch, H.-J. Reulen

ABSTRACT

Prognosis of malignant glioma is very unfavourable mainly due to minimal tumour remnants in the peritumoural tissue. Intralesionally applied radioimmunotherapy is a possible therapeutical option with the potential to improve survival of patients with malignant glioma. We investigated side effects and survival after surgery, conventional radiotherapy and additional radioimmunotherapy with labelled tenascin-antibodies in patients with malignant glioma.Methods: Since 1995, 37 patients were treated with radioimmunotherapy after resection and radiotherapy of a malignant glioma. Patients received antibodies labelled with yttrium-90 and iodine-131 in different doses into the tumour cavity via a previously implanted ommaya-reservoir. Treatment was applied in up to 8 cycles (mean 2.96 cycles) in time intervals of 6–8 weeks. Mean age was 46 years, histology was anaplastic astrocytoma in 13 patients and glioblastoma in 24 patients.Results: For the whole group median survival time has not yet been reached. For glioblastoma the median survival time is 17 months, 5-year survival probability for anaplastic astrocytoma is 85% approximately. Quality of life was acceptable. Acute side effects following treatment were headache, seizures and worsening of pre-existing neurological symptoms. Late side effects were skin necrosis and, in 1 case, a delayed aphasia probably due to a vascular lesion.Conclusion: Radioimmunotherapy prolonged survival time in a selected group of patients with malignant gliomas as compared to a historical control group. Patients with anaplastic astrocytomas seem to have more benefit from this therapy than patients with glioblastomas. More... »

PAGES

321-328

Identifiers

URI

http://scigraph.springernature.com/pub.10.1023/a:1023309927635

DOI

http://dx.doi.org/10.1023/a:1023309927635

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1043723074

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/12777085


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Radiation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glioma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunoconjugates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Iodine Radioisotopes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radioimmunotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tenascin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tissue Distribution", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Yttrium Radioisotopes", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Neurochirurgische Klinik der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5252.0", 
          "name": [
            "Neurochirurgische Klinik der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Goetz", 
        "givenName": "C.", 
        "id": "sg:person.01177702773.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177702773.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Servizio di medicina nucleare, Ospedale Maurizio Bufalini, Cesena, Italien", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Servizio di medicina nucleare, Ospedale Maurizio Bufalini, Cesena, Italien"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Riva", 
        "givenName": "P.", 
        "id": "sg:person.01177547630.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177547630.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinik und Poliklinik f\u00fcr Nuklearmedizin der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5252.0", 
          "name": [
            "Klinik und Poliklinik f\u00fcr Nuklearmedizin der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Poepperl", 
        "givenName": "G.", 
        "id": "sg:person.01272264470.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272264470.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinik und Poliklinik f\u00fcr Nuklearmedizin der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5252.0", 
          "name": [
            "Klinik und Poliklinik f\u00fcr Nuklearmedizin der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gildehaus", 
        "givenName": "F.J.", 
        "id": "sg:person.01030135266.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030135266.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Neurochirurgische Klinik der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5252.0", 
          "name": [
            "Neurochirurgische Klinik der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hischa", 
        "givenName": "A.", 
        "id": "sg:person.01217702663.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217702663.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinik und Poliklinik f\u00fcr Nuklearmedizin der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5252.0", 
          "name": [
            "Klinik und Poliklinik f\u00fcr Nuklearmedizin der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tatsch", 
        "givenName": "K.", 
        "id": "sg:person.01203226043.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203226043.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Neurochirurgische Klinik der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany", 
          "id": "http://www.grid.ac/institutes/grid.5252.0", 
          "name": [
            "Neurochirurgische Klinik der, Ludwig-Maximilians-Universit\u00e4t, M\u00fcnchen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reulen", 
        "givenName": "H.-J.", 
        "id": "sg:person.01167043552.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167043552.60"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1023/a:1005952925378", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019014245", 
          "https://doi.org/10.1023/a:1005952925378"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1006331416283", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014237854", 
          "https://doi.org/10.1023/a:1006331416283"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf03032361", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038705499", 
          "https://doi.org/10.1007/bf03032361"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-642-85039-4_15", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011103427", 
          "https://doi.org/10.1007/978-3-642-85039-4_15"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00177479", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015648301", 
          "https://doi.org/10.1007/bf00177479"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01052668", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020515683", 
          "https://doi.org/10.1007/bf01052668"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002590050549", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010084610", 
          "https://doi.org/10.1007/s002590050549"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s004320000188", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012351779", 
          "https://doi.org/10.1007/s004320000188"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2003-05", 
    "datePublishedReg": "2003-05-01", 
    "description": "Prognosis of malignant glioma is very unfavourable mainly due to minimal tumour remnants in the peritumoural tissue. Intralesionally applied radioimmunotherapy is a possible therapeutical option with the potential to improve survival of patients with malignant glioma. We investigated side effects and survival after surgery, conventional radiotherapy and additional radioimmunotherapy with labelled tenascin-antibodies in patients with malignant glioma.Methods: Since 1995, 37 patients were treated with radioimmunotherapy after resection and radiotherapy of a malignant glioma. Patients received antibodies labelled with yttrium-90 and iodine-131 in different doses into the tumour cavity via a previously implanted ommaya-reservoir. Treatment was applied in up to 8 cycles (mean 2.96 cycles) in time intervals of 6\u20138 weeks. Mean age was 46 years, histology was anaplastic astrocytoma in 13 patients and glioblastoma in 24 patients.Results: For the whole group median survival time has not yet been reached. For glioblastoma the median survival time is 17 months, 5-year survival probability for anaplastic astrocytoma is 85% approximately. Quality of life was acceptable. Acute side effects following treatment were headache, seizures and worsening of pre-existing neurological symptoms. Late side effects were skin necrosis and, in 1 case, a delayed aphasia probably due to a vascular lesion.Conclusion: Radioimmunotherapy prolonged survival time in a selected group of patients with malignant gliomas as compared to a historical control group. Patients with anaplastic astrocytomas seem to have more benefit from this therapy than patients with glioblastomas.", 
    "genre": "article", 
    "id": "sg:pub.10.1023/a:1023309927635", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "62"
      }
    ], 
    "keywords": [
      "median survival time", 
      "malignant gliomas", 
      "survival time", 
      "side effects", 
      "anaplastic astrocytoma", 
      "pre-existing neurological symptoms", 
      "Ommaya-Reservoir", 
      "acute side effects", 
      "late side effects", 
      "survival of patients", 
      "group of patients", 
      "historical control group", 
      "quality of life", 
      "additional radioimmunotherapy", 
      "locoregional radioimmunotherapy", 
      "neurological symptoms", 
      "skin necrosis", 
      "mean age", 
      "therapeutical options", 
      "vascular lesions", 
      "tumor remnants", 
      "conventional radiotherapy", 
      "tumor cavity", 
      "peritumoural tissue", 
      "patients", 
      "control group", 
      "radioimmunotherapy", 
      "gliomas", 
      "different doses", 
      "astrocytomas", 
      "glioblastoma", 
      "radiotherapy", 
      "survival", 
      "treatment", 
      "survival probability", 
      "resection", 
      "surgery", 
      "prognosis", 
      "group", 
      "seizures", 
      "symptoms", 
      "therapy", 
      "worsening", 
      "histology", 
      "lesions", 
      "necrosis", 
      "doses", 
      "yttrium-90", 
      "weeks", 
      "months", 
      "antibodies", 
      "iodine-131", 
      "more benefits", 
      "time interval", 
      "effect", 
      "age", 
      "aphasia", 
      "tissue", 
      "options", 
      "years", 
      "time", 
      "intervals", 
      "life", 
      "cases", 
      "benefits", 
      "cavity", 
      "experience", 
      "remnants", 
      "quality", 
      "potential", 
      "cycle", 
      "probability", 
      "minimal tumour remnants", 
      "possible therapeutical option", 
      "labelled tenascin-antibodies", 
      "tenascin-antibodies", 
      "whole group median survival time", 
      "group median survival time"
    ], 
    "name": "Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times", 
    "pagination": "321-328", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1043723074"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1023/a:1023309927635"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "12777085"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1023/a:1023309927635", 
      "https://app.dimensions.ai/details/publication/pub.1043723074"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_378.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1023/a:1023309927635"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/a:1023309927635'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/a:1023309927635'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/a:1023309927635'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/a:1023309927635'


 

This table displays all metadata directly associated to this object as RDF triples.

291 TRIPLES      22 PREDICATES      131 URIs      115 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1023/a:1023309927635 schema:about N042719b849794784938c381f34a43989
2 N0acf1ec401454bb0b0b03cf903fb2a24
3 N1063c9a26e1447c69834e6cb9ca22c50
4 N23fbeb3918364a49840afa8129ad4509
5 N2eec2248525f4b6fa66a437218b2a28b
6 N411b84fd689f4dd8ad5c32deb1a34287
7 N4749e943b9524b1da20b5b02d4969f8a
8 N4cdec6d10e3a486dbc34b71ce045462e
9 N6921a9440db249e9af9fba59b3588791
10 N6e4c3d4a86b747b78f863289433720fa
11 N793d6875bb4f4f25865fc674e5e4044b
12 N80acef7161df431f95904426a570801c
13 Nadff3cbe049048eb9a57ec3d8f87f204
14 Nb7bffada42174b089513ce3464dad48b
15 Nc06d05058f644f428fe8e77c112c37f7
16 Nc5d280199ae641a4a49d3ac0c4ed960c
17 Nda89fa754e06482695ad76f98614dbe3
18 Nde719cf544e94427b40297413f0a9838
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author N595ff2e444d44cf9b5022f6b2df7ea83
22 schema:citation sg:pub.10.1007/978-3-642-85039-4_15
23 sg:pub.10.1007/bf00177479
24 sg:pub.10.1007/bf01052668
25 sg:pub.10.1007/bf03032361
26 sg:pub.10.1007/s002590050549
27 sg:pub.10.1007/s004320000188
28 sg:pub.10.1023/a:1005952925378
29 sg:pub.10.1023/a:1006331416283
30 schema:datePublished 2003-05
31 schema:datePublishedReg 2003-05-01
32 schema:description Prognosis of malignant glioma is very unfavourable mainly due to minimal tumour remnants in the peritumoural tissue. Intralesionally applied radioimmunotherapy is a possible therapeutical option with the potential to improve survival of patients with malignant glioma. We investigated side effects and survival after surgery, conventional radiotherapy and additional radioimmunotherapy with labelled tenascin-antibodies in patients with malignant glioma.Methods: Since 1995, 37 patients were treated with radioimmunotherapy after resection and radiotherapy of a malignant glioma. Patients received antibodies labelled with yttrium-90 and iodine-131 in different doses into the tumour cavity via a previously implanted ommaya-reservoir. Treatment was applied in up to 8 cycles (mean 2.96 cycles) in time intervals of 6–8 weeks. Mean age was 46 years, histology was anaplastic astrocytoma in 13 patients and glioblastoma in 24 patients.Results: For the whole group median survival time has not yet been reached. For glioblastoma the median survival time is 17 months, 5-year survival probability for anaplastic astrocytoma is 85% approximately. Quality of life was acceptable. Acute side effects following treatment were headache, seizures and worsening of pre-existing neurological symptoms. Late side effects were skin necrosis and, in 1 case, a delayed aphasia probably due to a vascular lesion.Conclusion: Radioimmunotherapy prolonged survival time in a selected group of patients with malignant gliomas as compared to a historical control group. Patients with anaplastic astrocytomas seem to have more benefit from this therapy than patients with glioblastomas.
33 schema:genre article
34 schema:inLanguage en
35 schema:isAccessibleForFree false
36 schema:isPartOf N8d4ecac78c1b492aa8309601627acacd
37 Nb22016272a84459188a80883cc1be37f
38 sg:journal.1094205
39 schema:keywords Ommaya-Reservoir
40 acute side effects
41 additional radioimmunotherapy
42 age
43 anaplastic astrocytoma
44 antibodies
45 aphasia
46 astrocytomas
47 benefits
48 cases
49 cavity
50 control group
51 conventional radiotherapy
52 cycle
53 different doses
54 doses
55 effect
56 experience
57 glioblastoma
58 gliomas
59 group
60 group median survival time
61 group of patients
62 histology
63 historical control group
64 intervals
65 iodine-131
66 labelled tenascin-antibodies
67 late side effects
68 lesions
69 life
70 locoregional radioimmunotherapy
71 malignant gliomas
72 mean age
73 median survival time
74 minimal tumour remnants
75 months
76 more benefits
77 necrosis
78 neurological symptoms
79 options
80 patients
81 peritumoural tissue
82 possible therapeutical option
83 potential
84 pre-existing neurological symptoms
85 probability
86 prognosis
87 quality
88 quality of life
89 radioimmunotherapy
90 radiotherapy
91 remnants
92 resection
93 seizures
94 side effects
95 skin necrosis
96 surgery
97 survival
98 survival of patients
99 survival probability
100 survival time
101 symptoms
102 tenascin-antibodies
103 therapeutical options
104 therapy
105 time
106 time interval
107 tissue
108 treatment
109 tumor cavity
110 tumor remnants
111 vascular lesions
112 weeks
113 whole group median survival time
114 worsening
115 years
116 yttrium-90
117 schema:name Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times
118 schema:pagination 321-328
119 schema:productId N73c3ee48846a4de69b897b7a380c8007
120 N891205f4e2174ae0b48be42ba73598a8
121 Nca8251643efa40c8bf237076cfb99dbc
122 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043723074
123 https://doi.org/10.1023/a:1023309927635
124 schema:sdDatePublished 2022-01-01T18:13
125 schema:sdLicense https://scigraph.springernature.com/explorer/license/
126 schema:sdPublisher Nc3abab3f416347c7a924c14da6619935
127 schema:url https://doi.org/10.1023/a:1023309927635
128 sgo:license sg:explorer/license/
129 sgo:sdDataset articles
130 rdf:type schema:ScholarlyArticle
131 N042719b849794784938c381f34a43989 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Survival Rate
133 rdf:type schema:DefinedTerm
134 N08370c3d30e34e3da77587c13224671c rdf:first sg:person.01272264470.83
135 rdf:rest N4a396aec573d417da782fc1eaadad07a
136 N0acf1ec401454bb0b0b03cf903fb2a24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Aged
138 rdf:type schema:DefinedTerm
139 N1063c9a26e1447c69834e6cb9ca22c50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Immunoconjugates
141 rdf:type schema:DefinedTerm
142 N23fbeb3918364a49840afa8129ad4509 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Tissue Distribution
144 rdf:type schema:DefinedTerm
145 N24c3a6eeaf6e494fa346a859b91051ff rdf:first sg:person.01167043552.60
146 rdf:rest rdf:nil
147 N2bfe0116fdd84abfa0f0e059e53356b9 rdf:first sg:person.01177547630.17
148 rdf:rest N08370c3d30e34e3da77587c13224671c
149 N2eec2248525f4b6fa66a437218b2a28b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Prognosis
151 rdf:type schema:DefinedTerm
152 N405e35695f7d4cddb7384017fcb336fb rdf:first sg:person.01203226043.77
153 rdf:rest N24c3a6eeaf6e494fa346a859b91051ff
154 N411b84fd689f4dd8ad5c32deb1a34287 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Combined Modality Therapy
156 rdf:type schema:DefinedTerm
157 N4749e943b9524b1da20b5b02d4969f8a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Middle Aged
159 rdf:type schema:DefinedTerm
160 N4a396aec573d417da782fc1eaadad07a rdf:first sg:person.01030135266.67
161 rdf:rest Nea5d1c6035aa44018b675d03e72eb03e
162 N4cdec6d10e3a486dbc34b71ce045462e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Quality of Life
164 rdf:type schema:DefinedTerm
165 N595ff2e444d44cf9b5022f6b2df7ea83 rdf:first sg:person.01177702773.68
166 rdf:rest N2bfe0116fdd84abfa0f0e059e53356b9
167 N6921a9440db249e9af9fba59b3588791 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Iodine Radioisotopes
169 rdf:type schema:DefinedTerm
170 N6e4c3d4a86b747b78f863289433720fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Radioimmunotherapy
172 rdf:type schema:DefinedTerm
173 N73c3ee48846a4de69b897b7a380c8007 schema:name pubmed_id
174 schema:value 12777085
175 rdf:type schema:PropertyValue
176 N793d6875bb4f4f25865fc674e5e4044b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Yttrium Radioisotopes
178 rdf:type schema:DefinedTerm
179 N80acef7161df431f95904426a570801c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Brain Neoplasms
181 rdf:type schema:DefinedTerm
182 N891205f4e2174ae0b48be42ba73598a8 schema:name dimensions_id
183 schema:value pub.1043723074
184 rdf:type schema:PropertyValue
185 N8d4ecac78c1b492aa8309601627acacd schema:issueNumber 3
186 rdf:type schema:PublicationIssue
187 Nadff3cbe049048eb9a57ec3d8f87f204 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Female
189 rdf:type schema:DefinedTerm
190 Nb22016272a84459188a80883cc1be37f schema:volumeNumber 62
191 rdf:type schema:PublicationVolume
192 Nb7bffada42174b089513ce3464dad48b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Dose-Response Relationship, Radiation
194 rdf:type schema:DefinedTerm
195 Nc06d05058f644f428fe8e77c112c37f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Glioma
197 rdf:type schema:DefinedTerm
198 Nc3abab3f416347c7a924c14da6619935 schema:name Springer Nature - SN SciGraph project
199 rdf:type schema:Organization
200 Nc5d280199ae641a4a49d3ac0c4ed960c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Adult
202 rdf:type schema:DefinedTerm
203 Nca8251643efa40c8bf237076cfb99dbc schema:name doi
204 schema:value 10.1023/a:1023309927635
205 rdf:type schema:PropertyValue
206 Nda89fa754e06482695ad76f98614dbe3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Tenascin
208 rdf:type schema:DefinedTerm
209 Nde719cf544e94427b40297413f0a9838 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Humans
211 rdf:type schema:DefinedTerm
212 Nea5d1c6035aa44018b675d03e72eb03e rdf:first sg:person.01217702663.99
213 rdf:rest N405e35695f7d4cddb7384017fcb336fb
214 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
215 schema:name Medical and Health Sciences
216 rdf:type schema:DefinedTerm
217 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
218 schema:name Oncology and Carcinogenesis
219 rdf:type schema:DefinedTerm
220 sg:journal.1094205 schema:issn 0167-594X
221 1573-7373
222 schema:name Journal of Neuro-Oncology
223 schema:publisher Springer Nature
224 rdf:type schema:Periodical
225 sg:person.01030135266.67 schema:affiliation grid-institutes:grid.5252.0
226 schema:familyName Gildehaus
227 schema:givenName F.J.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030135266.67
229 rdf:type schema:Person
230 sg:person.01167043552.60 schema:affiliation grid-institutes:grid.5252.0
231 schema:familyName Reulen
232 schema:givenName H.-J.
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167043552.60
234 rdf:type schema:Person
235 sg:person.01177547630.17 schema:affiliation grid-institutes:None
236 schema:familyName Riva
237 schema:givenName P.
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177547630.17
239 rdf:type schema:Person
240 sg:person.01177702773.68 schema:affiliation grid-institutes:grid.5252.0
241 schema:familyName Goetz
242 schema:givenName C.
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177702773.68
244 rdf:type schema:Person
245 sg:person.01203226043.77 schema:affiliation grid-institutes:grid.5252.0
246 schema:familyName Tatsch
247 schema:givenName K.
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203226043.77
249 rdf:type schema:Person
250 sg:person.01217702663.99 schema:affiliation grid-institutes:grid.5252.0
251 schema:familyName Hischa
252 schema:givenName A.
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217702663.99
254 rdf:type schema:Person
255 sg:person.01272264470.83 schema:affiliation grid-institutes:grid.5252.0
256 schema:familyName Poepperl
257 schema:givenName G.
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272264470.83
259 rdf:type schema:Person
260 sg:pub.10.1007/978-3-642-85039-4_15 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011103427
261 https://doi.org/10.1007/978-3-642-85039-4_15
262 rdf:type schema:CreativeWork
263 sg:pub.10.1007/bf00177479 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015648301
264 https://doi.org/10.1007/bf00177479
265 rdf:type schema:CreativeWork
266 sg:pub.10.1007/bf01052668 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020515683
267 https://doi.org/10.1007/bf01052668
268 rdf:type schema:CreativeWork
269 sg:pub.10.1007/bf03032361 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038705499
270 https://doi.org/10.1007/bf03032361
271 rdf:type schema:CreativeWork
272 sg:pub.10.1007/s002590050549 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010084610
273 https://doi.org/10.1007/s002590050549
274 rdf:type schema:CreativeWork
275 sg:pub.10.1007/s004320000188 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012351779
276 https://doi.org/10.1007/s004320000188
277 rdf:type schema:CreativeWork
278 sg:pub.10.1023/a:1005952925378 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019014245
279 https://doi.org/10.1023/a:1005952925378
280 rdf:type schema:CreativeWork
281 sg:pub.10.1023/a:1006331416283 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014237854
282 https://doi.org/10.1023/a:1006331416283
283 rdf:type schema:CreativeWork
284 grid-institutes:None schema:alternateName Servizio di medicina nucleare, Ospedale Maurizio Bufalini, Cesena, Italien
285 schema:name Servizio di medicina nucleare, Ospedale Maurizio Bufalini, Cesena, Italien
286 rdf:type schema:Organization
287 grid-institutes:grid.5252.0 schema:alternateName Klinik und Poliklinik für Nuklearmedizin der, Ludwig-Maximilians-Universität, München, Germany
288 Neurochirurgische Klinik der, Ludwig-Maximilians-Universität, München, Germany
289 schema:name Klinik und Poliklinik für Nuklearmedizin der, Ludwig-Maximilians-Universität, München, Germany
290 Neurochirurgische Klinik der, Ludwig-Maximilians-Universität, München, Germany
291 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...